Secondary iron overload.

Transfusion therapy for inherited anemias and acquired refractory anemias both improves the quality of life and prolongs survival. A consequence of chronic transfusion therapy is secondary iron overload, which adversely affects the function of the heart, the liver and other organs. This session will review the use of iron chelating agents in the management of transfusion-induced secondary iron overload. In Section I Dr. John Porter describes techniques for the administration of deferoxamine that exploit the pharmacokinetic properties of the drug and minimize potential toxic side effects. The experience with chelation therapy in patients with thalassemia and sickle cell disease will be reviewed and guidelines will be suggested for chelation therapy of chronically transfused adults with refractory anemias. In Section II Dr. Nancy Olivieri examines the clinical consequences of transfusion-induced secondary iron overload and suggests criteria useful in determining the optimal timing of the initiation of chelation therapy. Finally, Dr. Olivieri discusses the clinical trials evaluating orally administered iron chelators.

[1]  R. Hider,et al.  Synthesis of 2-amido-3-hydroxypyridin-4(1H)-ones: novel iron chelators with enhanced pFe3+ values. , 2001, Bioorganic & medicinal chemistry.

[2]  Z. Cabantchik,et al.  Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. , 2001, Blood.

[3]  E. Vichinsky Consensus document for transfusion-related iron overload. , 2001, Seminars in hematology.

[4]  N. Olivieri,et al.  Progression of iron overload in sickle cell disease. , 2001, Seminars in hematology.

[5]  R. Galanello Iron chelation: new therapies. , 2001, Seminars in hematology.

[6]  S. Sheth,et al.  Noninvasive methods for quantitative assessment of transfusional iron overload in sickle cell disease. , 2001, Seminars in hematology.

[7]  S. Ballas Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. , 2001, Seminars in hematology.

[8]  K. Ohene‐Frempong Indications for red cell transfusion in sickle cell disease. , 2001, Seminars in hematology.

[9]  R. Fischer,et al.  Factors Influencing Effectiveness of Deferiprone in a Thalassaemia major Clinical Setting , 2001, Acta Haematologica.

[10]  R. Fischer,et al.  Using SQUID biomagnetic liver susceptometry in the treatment of thalassemia and other iron loading diseases. , 2000, Transfusion science.

[11]  R. Lindeman,et al.  The Sydney Children's Hospital experience with the oral iron chelator deferiprone (L1). , 2000, Transfusion science.

[12]  B. Wonke,et al.  Combined oral and parenteral iron chelation in beta thalassaemia major. , 2000, The Medical journal of Malaysia.

[13]  M. Kami,et al.  Hepatic iron concentration and total body iron stores in thalassemia major. , 2000, The New England journal of medicine.

[14]  D. Weatherall,et al.  Oral iron chelation therapy for thalassaemia: an uncertain scene. Annotation , 2000 .

[15]  D. Weatherall,et al.  Oral iron chelation therapy for thalassaemia: an uncertain scene , 2000, British journal of haematology.

[16]  A. Hoffbrand,et al.  Hepatic iron concentration combined with long‐term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major , 2000, British journal of haematology.

[17]  P. Harmatz,et al.  Severity of Iron Overload in Patients with Sickle Cell Disease Receiving Chronic Red Blood Cell Transfusion Therapy , 2000, Blood.

[18]  Matthew Darlison,et al.  Survival in β-thalassaemia major in the UK: data from the UK Thalassaemia Register , 2000, The Lancet.

[19]  R. Fischer,et al.  Serum ferritin iron in iron overload and liver damage: correlation to body iron stores and diagnostic relevance. , 2000, The Journal of laboratory and clinical medicine.

[20]  G. Aprili,et al.  Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload. , 2000, Blood.

[21]  V. Farina,et al.  Longitudinal assessment of cardiac status by echocardiographic evaluation of left ventricular diastolic function in thalassaemic children. , 2000, Acta paediatrica.

[22]  J. Porter,et al.  Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β-thalassemia , 2000 .

[23]  Vullo,et al.  Safety profile of the oral iron chelator deferiprone: a multicentre study , 2000, British journal of haematology.

[24]  J. Porter,et al.  Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. , 2000, Blood.

[25]  E. Vichinsky,et al.  Transfusion practice for patients with sickle cell disease. , 1999, Current opinion in hematology.

[26]  L. Bonetta Canadian fight over thalassemia drug worsens , 1999, Nature Medicine.

[27]  N. Çetingül,et al.  Sequential Use of Deferiprone and Desferrioxamine in Primary School Children with Thalassaemia major in Turkey , 1999, Acta Haematologica.

[28]  N. Olivieri The β-Thalassemias , 1999 .

[29]  H. Bonkovsky,et al.  Hepatic iron concentration: noninvasive estimation by means of MR imaging techniques. , 1999, Radiology.

[30]  R. Fischer,et al.  Assessment of iron stores in children with transfusion siderosis by biomagnetic liver susceptometry , 1999, American journal of hematology.

[31]  T. Einarson,et al.  Meta-analytic review of the clinical effectiveness of oral deferiprone (L1) , 1999, European Journal of Clinical Pharmacology.

[32]  N. Olivieri The beta-thalassemias. , 1999, The New England journal of medicine.

[33]  G. Piatti,et al.  Beta-thalassemia and pulmonary function. , 1999, Haematologica.

[34]  Wright,et al.  Combined therapy with deferiprone and desferrioxamine , 1998, British journal of haematology.

[35]  L. Bonetta Inquiry into clinical trial scandal at Canadian research hospital , 1998, Nature Medicine.

[36]  K. Fleming,et al.  Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. , 1998, The New England journal of medicine.

[37]  R. Hebbel,et al.  The iron chelator L1 potentiates oxidative DNA damage in iron-loaded liver cells. , 1998, Blood.

[38]  G. Link,et al.  Pathophysiology of Iron Overload a , 1998, Annals of the New York Academy of Sciences.

[39]  A. Piga,et al.  A Multi‐Center Safety Trial of the Oral Iron Chelator Deferiprone , 1998, Annals of the New York Academy of Sciences.

[40]  G. Link,et al.  Iron Chelators for Thalassaemia , 1998, British journal of haematology.

[41]  C. Howes,et al.  A Trial to Investigate the Relationship between DFO Pharmacokinetics and Metabolism and DFO‐Related Toxicity , 1998, Annals of the New York Academy of Sciences.

[42]  M. Cappellini,et al.  Survival and Disease Complications in Thalassemia Major , 1998, Annals of the New York Academy of Sciences.

[43]  A. Hirt,et al.  Liver iron and fibrosis during long‐term treatment with deferiprone in Swiss thalassaemic patients , 1998, British journal of haematology.

[44]  G. Aprili,et al.  Subcutaneous bolus injection of deferoxamine in adult patients affected by onco-hematologic diseases and iron overload. , 1998, Haematologica.

[45]  A. Hoffbrand,et al.  Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. , 1998, Blood.

[46]  P. Mazza,et al.  Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia. , 1998, Haematologica.

[47]  A. Giovagnoni,et al.  Limitations of magnetic resonance imaging in measurement of hepatic iron. , 1997, Blood.

[48]  Z. Du,et al.  Pulmonary hypertension in patients with thalassemia major. , 1997, American heart journal.

[49]  R. Hider,et al.  Inhibition of iron-containing metalloenzymes by 3-hydroxypyridin-4-one chelators , 1997 .

[50]  A. Rosman,et al.  Serum Ferritin Iron, a New Test, Measures Human Body Iron Stores Unconfounded by Inflammation , 1997, Stem cells.

[51]  P. Milgram,et al.  Chelation and mobilization of cellular iron by different classes of chelators. , 1997, Molecular pharmacology.

[52]  P. Alberti,et al.  Desferrioxamine ototoxicity in an adult transfusion-dependent population. , 1997, The Journal of otolaryngology.

[53]  R. Hider,et al.  Metabolism and pharmacokinetics of 1-(2'-trimethylacetoxyethyl)-2-ethyl-3-hydroxypyridin-4-one (CP117) in the rat. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[54]  M. Sacco,et al.  Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone) , 1997, British journal of haematology.

[55]  G. Brittenham,et al.  Iron-chelating therapy and the treatment of thalassemia. , 1997, Blood.

[56]  C. Cooper,et al.  The Relationship of Intracellular Iron Chelation to the Inhibition and Regeneration of Human Ribonucleotide Reductase* , 1996, The Journal of Biological Chemistry.

[57]  R. Abeysinghe,et al.  Kinetics of removal and reappearance of non-transferrin-bound plasma iron with deferoxamine therapy. , 1996, Blood.

[58]  W. Y. Wang,et al.  Lungs in thalassaemia major patients receiving regular transfusion. , 1996, The European respiratory journal.

[59]  G. Koren,et al.  The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels. , 1996, International journal of clinical pharmacology and therapeutics.

[60]  C. Cooper,et al.  The Environment of the Lipoxygenase Iron Binding Site Explored with Novel Hydroxypyridinone Iron Chelators (*) , 1996, The Journal of Biological Chemistry.

[61]  D. Häussinger,et al.  Long-term survival in patients with hereditary hemochromatosis. , 1996, Gastroenterology.

[62]  A. Hoffbrand Oral iron chelation. , 1996, Seminars in hematology.

[63]  A. Piga,et al.  Results of long-term iron-chelating therapy. , 1996, Acta haematologica.

[64]  A. Hoffbrand,et al.  Results of long‐term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators , 1995, British journal of haematology.

[65]  S. Andò,et al.  Multicentre study on prevalence of endocrine complications in thalassaemia major , 1995, Clinical endocrinology.

[66]  D. Templeton,et al.  Modulation by iron loading and chelation of the uptake of non-transferrin-bound iron by human liver cells. , 1995, Biochimica et biophysica acta.

[67]  G. Koren,et al.  Iron-chelation therapy with oral deferiprone in patients with thalassemia major. , 1995, The New England journal of medicine.

[68]  D. Nathan An orally active iron chelator. , 1995, The New England journal of medicine.

[69]  G. Lucarelli,et al.  Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies , 1995, British journal of haematology.

[70]  F. Cerutti,et al.  Insulin resistance and hyperinsulinemia in homozygous β-thalassemia☆ , 1995 .

[71]  A. Hoffbrand,et al.  Pharmacokinetics of the oral iron chelator deferiprone (L1) in patients with iron overload , 1995, British journal of haematology.

[72]  D. Loukopoulos,et al.  Pulmonary hypertension and right heart failure in patients with beta-thalassemia intermedia. , 1995, Chest.

[73]  P. Toutouzas,et al.  Myocarditis in β-Thalassemia Major A Cause of Heart Failure , 1995 .

[74]  F. Cerutti,et al.  Insulin resistance and hyperinsulinemia in homozygous beta-thalassemia. , 1995, Metabolism: clinical and experimental.

[75]  P. Toutouzas,et al.  Myocarditis in beta-thalassemia major. A cause of heart failure. , 1995, Circulation.

[76]  P. van Eyken,et al.  Iron concentration and distribution in the newborn liver. , 2008, Liver.

[77]  A. Hoffbrand,et al.  Deferiprone‐associated myelotoxicity , 1994, European journal of haematology.

[78]  J. H. MacMillan,et al.  Survival in Medically Treated Patients with Homozygous β-Thalassemia , 1994 .

[79]  C. McLaren,et al.  Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. , 1994, The New England journal of medicine.

[80]  G. Koren,et al.  Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease. , 1994, Blood.

[81]  P. Dobbin,et al.  Synthesis, Physicochemical Properties, and Biological Evaluation of N- Substituted 2-Alkyl-3-hydroxy-4(1H)-pyridinones: Orally Active Iron Chelators with Clinical Potential. , 1994 .

[82]  R. Abeysinghe,et al.  Lessons from preclinical and clinical studies with 1,2-diethyl-3-hydroxypyridin-4-one, CP94 and related compounds. , 1994, Advances in experimental medicine and biology.

[83]  R. Hider,et al.  Iron chelator design. , 1994, Advances in experimental medicine and biology.

[84]  J. H. MacMillan,et al.  Survival in medically treated patients with homozygous beta-thalassemia. , 1994, The New England journal of medicine.

[85]  S. Menahem,et al.  Prevention of heart disease by subcutaneous desferrioxamine in patients with thalassaemia major. , 1993, Australian and New Zealand journal of medicine.

[86]  J. Porter,et al.  Subcellular distribution of desferrioxamine and hydroxypyridin‐4‐one chelators in K562 cells affects chelation of intracellular iron pools , 1993, British journal of haematology.

[87]  G. Brittenham,et al.  Contrasting interspecies efficacy and toxicology of 1, 2 ‐diethy 1–3 ‐hydroxypyridin‐4‐one, CP9 4, relates to differing metabolism of the iron chelating site , 1993, British journal of haematology.

[88]  R. Chatterjee,et al.  Prospective study of the hypothalamic‐pituitary axis in thalassaemic patients who developed secondary amenorrhoea , 1993, Clinical endocrinology.

[89]  D. van der Helm,et al.  Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential. , 1993, Journal of medicinal chemistry.

[90]  R. Abeysinghe,et al.  Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients. , 1993, Drug metabolism and disposition: the biological fate of chemicals.

[91]  D. Templeton,et al.  Effects of iron loading on uptake, speciation, and chelation of iron in cultured myocardial cells. , 1993, The Journal of laboratory and clinical medicine.

[92]  P. Bentley,et al.  Toxicity of oral iron chelator L1 , 1993, The Lancet.

[93]  L. Gullo,et al.  Morphologic and Functional Evaluation of the Exocrine Pancreas in β‐Thalassemia Major , 1993, Pancreas.

[94]  R. Abeysinghe,et al.  In vivo and in vitro effects of 3-hydroxypyridin-4-one chelators on murine hemopoiesis. , 1993, Experimental hematology.

[95]  R. Puniyani,et al.  Long‐term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trial , 1992, British journal of haematology.

[96]  R. Hider,et al.  Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemia cell lines. , 1992, Cancer research.

[97]  A. Hoffbrand,et al.  Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. , 1992, Blood.

[98]  I. Adamson,et al.  Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning , 1992, The Lancet.

[99]  M. Freedman,et al.  Growth failure and bony changes induced by deferoxamine. , 1992, The American journal of pediatric hematology/oncology.

[100]  G. Lescoat,et al.  Liver fibrosis in genetic hemochromatosis. Respective roles of iron and non-iron-related factors in 127 homozygous patients. , 1992, Journal of hepatology.

[101]  G. Koren,et al.  Reduction of tissue iron stores and normalization of serum ferritin during treatment with the oral iron chelator L1 in thalassemia intermedia. , 1992, Blood.

[102]  G. Koren,et al.  The effects of subcutaneous deferoxamine administration on renal function in thalassemia major. , 1991, International journal of hematology.

[103]  S. Singhal,et al.  Fatal systemic lupus erythematosus in patient taking oral iron chelator L1 , 1991, The Lancet.

[104]  G. Koren,et al.  Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients , 1990, The Lancet.

[105]  G. Kontoghiorghes,et al.  Pharmacokinetic studies in humans with the oral iron chelator 1,2‐dimethyl‐3‐hydroxypyrid‐4‐one , 1990, Clinical pharmacology and therapeutics.

[106]  R. Hider,et al.  Separation and identification of desferrioxamine and its iron chelating metabolites by high-performance liquid chromatography and fast atom bombardment mass spectrometry: choice of complexing agent and application to biological fluids. , 1990, Analytical biochemistry.

[107]  M. Freedman,et al.  Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions. , 1990, American journal of diseases of children.

[108]  B. Alter Agranulocytosis and thrombocytopenia, Blackfan-Diamond anaemia, and oral chelation , 1990, The Lancet.

[109]  D. Porcelli,et al.  Hypothyroidism in patients with thalassemia syndromes. , 1990, Acta haematologica.

[110]  J. Hazell,et al.  Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage , 1989, British journal of haematology.

[111]  P. Veys,et al.  AGRANULOCYTOSIS AND THROMBOCYTOPENIA IN PATIENT WITH BLACKFAN-DIAMOND ANAEMIA DURING ORAL CHELATOR TRIAL , 1989, The Lancet.

[112]  A. Piga,et al.  SURVIVAL AND CAUSES OF DEATH IN THALASSAEMIA MAJOR , 1989, The Lancet.

[113]  E. Huehns,et al.  Iron mobilization from hepatocyte monolayer cultures by chelators: the importance of membrane permeability and the iron-binding constant. , 1988, Blood.

[114]  F. Cucca,et al.  Deferoxamine-induced growth retardation in patients with thalassemia major. , 1988, The Journal of pediatrics.

[115]  L. Luzzatto,et al.  HIGH‐DOSE DESFERRIOXAMINE AS A CAUSE OF GROWTH FAILURE IN THALASSEMIC PATIENTS , 1988, European journal of haematology.

[116]  G. Brittenham,et al.  The effect of erythroid hyperplasia on iron balance. , 1988, Blood.

[117]  C. Sklar,et al.  Adrenal function in thalassemia major following long-term treatment with multiple transfusions and chelation therapy. Evidence for dissociation of cortisol and adrenal androgen secretion. , 1987, American journal of diseases of children.

[118]  E. Chew,et al.  Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. , 1986, The New England journal of medicine.

[119]  Margot J. Taylor,et al.  Visual and Auditory Neurotoxicity in Patients Receiving Subcutaneous Deferoxamine Infusions , 1986 .

[120]  R. Sherman,et al.  Thrombocytopenia associated with intravenous desferrioxamine. , 1985, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[121]  J. Lunec,et al.  Cerebral and ocular toxicity induced by desferrioxamine. , 1985, The Quarterly journal of medicine.

[122]  S. Colan,et al.  Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. , 1985, The New England journal of medicine.

[123]  R. Robins-Browne,et al.  Effects of iron and desferrioxamine on infections with Yersinia enterocolitica , 1985, Infection and immunity.

[124]  R. Dick,et al.  Liver biopsy today. The Royal Free Hospital experience. , 1985, Journal of hepatology.

[125]  G. Arden,et al.  Ocular changes in patients undergoing long-term desferrioxamine treatment. , 1984, The British journal of ophthalmology.

[126]  A. Piga,et al.  Cirrhosis associated with multiple transfusions in thalassaemia. , 1984, Archives of disease in childhood.

[127]  J. Bousquet,et al.  RAPID DESENSITISATION FOR DESFERRIOXAMINE ANAPHYLACTOID REACTIONS , 1983, The Lancet.

[128]  G. Arden,et al.  OCULAR TOXICITY OF HIGH-DOSE INTRAVENOUS DESFERRIOXAMINE , 1983, The Lancet.

[129]  B. Bacon,et al.  Hepatic lipid peroxidation in vivo in rats with chronic iron overload. , 1983, The Journal of clinical investigation.

[130]  J. Tripp,et al.  Magnetic-susceptibility measurement of human iron stores. , 1982, The New England journal of medicine.

[131]  M. Pippard,et al.  Ferrioxamine excretion in iron-loaded man. , 1982, Blood.

[132]  J. Leonard,et al.  Continuous RBC transfusions in a patient with sickle cell disease. , 1982, Archives of internal medicine.

[133]  L. Rosenwasser,et al.  RAPID DESENSITISATION FOR DESFERRIOXAMINE ANAPHYLACTIC REACTION , 1981, The Lancet.

[134]  D. Weatherall,et al.  IRON ABSORPTION AND LOADING IN β-THALASSÆMIA INTERMEDIA , 1979, The Lancet.

[135]  A. Jacobs,et al.  Studies in Desferrioxamine and Ferrioxamine Metabolism in Normal and Iron‐Loaded Subjects , 1979, British journal of haematology.

[136]  M. Skolnick,et al.  Hereditary hemochromatosis. Phenotypic expression of the disease. , 1979, The New England journal of medicine.

[137]  E. Rachmilewitz,et al.  Mechanism of Desferrioxamine‐Induced Iron Excretion in Thalassaemia , 1979, British journal of haematology.

[138]  D. Weatherall,et al.  Iron absorption and loading in beta-thalassaemia intermedia. , 1979, Lancet.

[139]  E. Rachmilewitz,et al.  Non‐Specific Serum Iron in Thalassaemia: an Abnormal Serum Iron Fraction of Potential Toxicity , 1978, British journal of haematology.

[140]  A. Cerami,et al.  Mechanism of iron chelation in the hypertransfused rat: definition of two alternative pathways of iron mobilization. , 1978, The Journal of laboratory and clinical medicine.

[141]  D. Weatherall,et al.  PREVENTION OF IRON LOADING IN TRANSFUSION-DEPENDENT THALASSÆMIA , 1978, The Lancet.

[142]  W. Anderson,et al.  Continuous Subcutaneous Administration of Deferoxamine in Patients with Iron Overload , 1977 .

[143]  A. Hoffbrand,et al.  SUBCUTANEOUS INFUSION AND INTRAMUSCULAR INJECTION OF DESFERRIOXAMINE IN PATIENTS WITH TRANSFUSIONAL IRON OVERLOAD , 1976, The Lancet.

[144]  H. B. Neustein,et al.  The liver in thalassaemia major: ultrastructural observations. , 1976, Ciba Foundation symposium.

[145]  D. Flynn,et al.  Long-term Chelation Therapy in Thalassaemia Major: Effect on Liver Iron Concentration, Liver Histology, and Clinical Progress , 1974, British medical journal.

[146]  W. Roberts,et al.  Iron in the heart. Etiology and clinical significance. , 1971, The American journal of medicine.

[147]  J. B. Clegg,et al.  The thalassaemia syndromes , 1965 .

[148]  J. Wyatt,et al.  The effect of long survival on the pathology of thalassaemia major. , 1961, The Journal of pathology and bacteriology.

[149]  M. Margolies,et al.  Liver disease in sickle cell anemia; a correlation of clinical, biochemical, histologic and histochemical observations. , 1955, The American journal of medicine.

[150]  A. Frumin,et al.  Exogenous hemochromatosis in sickle cell anemia. , 1953, Gastroenterology.

[151]  C. Conley,et al.  [The liver in sickle cell anemia]. , 1953, Bulletin of the Johns Hopkins Hospital.

[152]  L. W. Diggs,et al.  PATHOLOGY OF SICKLE CELL ANEMIA , 1934 .